Oraya Therapeutics Expanding AMD Wet Therapy Into Europe

Jul 23 2014

NEWARK, California—Oraya Therapeutics said it is expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the UK and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

According to the company, the recognition of Oraya Therapy as an important option in the wet AMD treatment regimen is illustrated by both its rapid adoption and by insurance coverage of the therapy in the UK, Germany and Switzerland. Royal Hallamshire Hospital, part of the Sheffield Teaching Hospitals NHS Foundation Trust and the first National Health Service hospital in the UK to offer Oraya Therapy, began treating patients in April. Several additional NHS hospitals are expected to offer Oraya Therapy by the end of the year.

In Germany, the four centers offering Oraya Therapy are University Hospital Essen, University Hospital Schleswig-Holstein Campus Luebeck, University Hospital Freiburg, and the Medical Care Center of the University Hospital of Cologne. These will soon be joined by additional locations that are working toward adding Oraya Therapy before the end of 2014.

Anti-VEGF injections transformed the care of wet AMD patients when the treatment first became available, yet the limitations of this approach are well known.  Anti-VEGF therapy places a significant burden on patients and providers alike, primarily due to the frequency of injections required. Consequently, many patients are unable to maintain the level of injection therapy needed to provide optimum vision results. Wet AMD is the primary cause of blindness in developed countries. This challenge is becoming greater every year with the rapid growth of the aging population throughout Europe due to the “Baby Boom” generation.

Oraya Therapeutics is a privately held company developing innovative and non-invasive therapies for diseases of the eye.

Medical Device Daily, Volume 18, No. 140, July 23rd, 2014